Literature DB >> 17458946

Structure-based design, synthesis, and A-site rRNA cocrystal complexes of functionally novel aminoglycoside antibiotics: C2" ether analogues of paromomycin.

Stephen Hanessian1, Janek Szychowski, Susanta Sekhar Adhikari, Guillermo Vasquez, Pachamuthu Kandasamy, Eric E Swayze, Michael T Migawa, Ray Ranken, Boris François, Julia Wirmer-Bartoschek, Jiro Kondo, Eric Westhof.   

Abstract

A series of 2"-O-substituted ether analogues of paromomycin were prepared based on new site-selective functionalizations. X-ray cocrystal complexes of several such analogues revealed a new mode of binding in the A-site rRNA, whereby rings I and II adopted the familiar orientation and position previously observed with paromomycin, but rings III and IV were oriented differently. With few exceptions, all of the new analogues showed potent inhibitory activity equal or better than paromomycin against a sensitive strain of S. aureus. Single digit microM MIC values were obtained against E. coli, with some of the ether appendages containing polar or basic end groups. Two analogues showed excellent survival rate in a mouse septicemia protection assay. Preliminary histopathological analysis of the kidney showed no overt signs of toxicity, while controls with neomycin and kanamycin were toxic at lower doses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17458946     DOI: 10.1021/jm061200+

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  A peptide nucleic acid-aminosugar conjugate targeting transactivation response element of HIV-1 RNA genome shows a high bioavailability in human cells and strongly inhibits tat-mediated transactivation of HIV-1 transcription.

Authors:  Indrajit Das; Jérôme Désiré; Dinesh Manvar; Isabelle Baussanne; Virendra N Pandey; Jean-Luc Décout
Journal:  J Med Chem       Date:  2012-06-22       Impact factor: 7.446

2.  Inhibition of aminoglycoside-deactivating enzymes APH(3')-IIIa and AAC(6')-Ii by amphiphilic paromomycin O2''-ether analogues.

Authors:  Janek Szychowski; Jiro Kondo; Omar Zahr; Karine Auclair; Eric Westhof; Stephen Hanessian; Jeffrey W Keillor
Journal:  ChemMedChem       Date:  2011-09-08       Impact factor: 3.466

3.  New trends in aminoglycosides use.

Authors:  Marina Y Fosso; Yijia Li; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

4.  A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.

Authors:  Nishad Thamban Chandrika; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2015-11-19       Impact factor: 3.597

Review 5.  Comprehensive review of chemical strategies for the preparation of new aminoglycosides and their biological activities.

Authors:  Nishad Thamban Chandrika; Sylvie Garneau-Tsodikova
Journal:  Chem Soc Rev       Date:  2018-02-19       Impact factor: 54.564

6.  Antifungal Amphiphilic Aminoglycosides.

Authors:  C-W T Chang; J Y Takemoto
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

Review 7.  Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections.

Authors:  Kristin J Labby; Sylvie Garneau-Tsodikova
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

8.  Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.

Authors:  Nishad Thamban Chandrika; Keith D Green; Jacob L Houghton; Sylvie Garneau-Tsodikova
Journal:  ACS Med Chem Lett       Date:  2015-09-30       Impact factor: 4.345

9.  Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.

Authors:  Marina Y Fosso; Sanjib K Shrestha; Keith D Green; Sylvie Garneau-Tsodikova
Journal:  J Med Chem       Date:  2015-12-01       Impact factor: 7.446

10.  Structural basis of APH(3')-IIIa-mediated resistance to N1-substituted aminoglycoside antibiotics.

Authors:  Desiree H Fong; Albert M Berghuis
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.